Bio2Skin, the first clinically skin-preserving biomaterial replacing silicones/acrylate as medical skin adhesives
BH4U's Bio2Skin is a revolutionary glueless medical adhesive that minimizes skin injuries from prolonged use, offering a safe, cost-effective solution for external medical devices.
Projectdetails
Introduction
External medical devices, such as ostomy pouches, wound dressings, or wearable electronic devices, require the use of medical adhesives for their attachment to the skin.
Problem Statement
However, prolonged use of current medical adhesives is associated with serious adverse skin reactions, known as MARSI (Medical Adhesives-Related Skin Injuries). This underreported issue is prevalent in 25% of wound care cases and is associated with enormous health care and economic burdens.
Solution Overview
BH4U aims to address this challenge with Bio2Skin.
Product Features
- A patented revolutionary glueless medical adhesive
- Utilizes the natural features of the skin to establish a water-based link
- Overcomes the disadvantages of acrylic/silicone adhesives
Benefits
Bio2Skin is a bio-based, cost-effective, recyclable solution offering:
- Gentle, safe adhesion
- Kind removal
Market Potential
The product has a potential market value of over 250M EUR by 2030. It will be sold under license to medical adhesive manufacturers and external medical device manufacturers.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.492.571 |
Totale projectbegroting | € 2.492.571 |
Tijdlijn
Startdatum | 1-11-2024 |
Einddatum | 31-10-2026 |
Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- BESTHEALTH4U LDApenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
A new cardioprotective drug for acute treatment of myocardial infarctionResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Clear, scalable and scientific framework to measure terrestrial biodiversity3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value. | EIC Accelerator | € 2.252.714 | 2024 | Details |
Novel and Scalable microbial products for REgenerative agricultureN-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data SecurityQuside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors. | EIC Accelerator | € 2.499.999 | 2024 | Details |
A new cardioprotective drug for acute treatment of myocardial infarction
ResoTher aims to validate RTP-026, an immunomodulating therapy, to reduce heart damage and HF risk post-myocardial infarction through Phase II clinical studies.
Clear, scalable and scientific framework to measure terrestrial biodiversity
3Bee leverages IoT, wildlife monitoring, and satellite data to measure and regenerate biodiversity, generating certified Biodiversity Credits for corporations to enhance ESG reporting and brand value.
Novel and Scalable microbial products for REgenerative agriculture
N-Spire aims to revolutionize agriculture by creating a sustainable bioactive fertilizer through innovative manufacturing techniques, enhancing soil health and reducing chemical dependency.
Quantum-based Randomness Processing Units (RPUs) for High-Performance Computation and Data Security
Quside's Randomness Processing Unit (RPU) accelerates stochastic HPC and PQ cryptography by optimizing random workloads, enhancing efficiency and performance across various sectors.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Bioinspired living skin for architectureThe ARCHI-SKIN project aims to develop a bioactive protective coating using fungal biofilms to enhance the durability and functionality of various materials through innovative design and in-situ methods. | ERC COG | € 1.999.000 | 2022 | Details |
Bioactive Tissue Sealant for Enhanced Wound RepairBioTisSeal aims to create bioactive tissue sealants using gelatin methacryloyl and aptamers for enhanced wound healing and market readiness, addressing current limitations in wound care. | ERC POC | € 150.000 | 2022 | Details |
SKIN MICROBIAL DEVICESSKINDEV aims to develop Smart Skin Microbial Devices for non-invasive monitoring and treatment of atopic dermatitis through innovative sensing technologies and genetic engineering. | EIC Pathfinder | € 1.718.408 | 2023 | Details |
Personalised Bioelectronics for Epithelial RepairProBER aims to develop personalized bioelectronic wound dressings using conformal DC electrodes to enhance healing speed and efficiency in chronic wounds, preparing for clinical studies. | ERC POC | € 150.000 | 2023 | Details |
Bioinspired living skin for architecture
The ARCHI-SKIN project aims to develop a bioactive protective coating using fungal biofilms to enhance the durability and functionality of various materials through innovative design and in-situ methods.
Bioactive Tissue Sealant for Enhanced Wound Repair
BioTisSeal aims to create bioactive tissue sealants using gelatin methacryloyl and aptamers for enhanced wound healing and market readiness, addressing current limitations in wound care.
SKIN MICROBIAL DEVICES
SKINDEV aims to develop Smart Skin Microbial Devices for non-invasive monitoring and treatment of atopic dermatitis through innovative sensing technologies and genetic engineering.
Personalised Bioelectronics for Epithelial Repair
ProBER aims to develop personalized bioelectronic wound dressings using conformal DC electrodes to enhance healing speed and efficiency in chronic wounds, preparing for clinical studies.